Literature DB >> 18705289

Approach to patients with pulmonary embolism in a surgical intensive care unit.

Leonidas Grigorakos1, Evangelia Sotiriou, P Myrianthefs, Anastasia Michail, Despina Koulendi, Vasilis Zidianakis, K Gianakopoulos, G Baltopoulos.   

Abstract

BACKGROUND/AIMS: Pulmonary embolism (PE) is a potentially life threatening disease. Clinical signs and symptoms allow the clinician to determine the pretest probability of someone having pulmonary embolism but are insufficient to diagnose or rule out the condition. This paper aims to study the clinical presentation, identify the risk factors and evaluate the diagnostic strategies and management of patients with PE.
METHODOLOGY: The medical files of 69 patients were searched, who were diagnosed with PE and who were admitted to the Surgical Care Unit.
RESULTS: Dyspnea, pleuritic pain, haemoptysis, fever and cough were the most common presenting symptoms. Risk factors for PE were found in 90% of cases. D-dimers assay was elevated in all cases (100%) and the other diagnostic strategies used showed great accuracy in confirming the pretest probabilities of PE. It is of high importance that 75% of the patients had deep vein thrombosis as assessed by venous ultrasonography. Mortality due to PE was approximately 6.9%.
CONCLUSIONS: PE can be often overlooked with hazardous consequences. Clinical evaluation in combination with spiral CT or lung scintigraphy and vein ultrasound and D-dimer level can establish the diagnosis in the majority of patients so that effective treatment to be started as soon as possible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18705289

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  1 in total

1.  DVT surveillance program in the ICU: analysis of cost-effectiveness.

Authors:  Ajai K Malhotra; Stephanie R Goldberg; Laura McLay; Nancy R Martin; Luke G Wolfe; Mark M Levy; Vishal Khiatani; Todd C Borchers; Therese M Duane; Michel B Aboutanos; Rao R Ivatury
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.